Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 1999 Jan 29;13(1):35–39. doi: 10.1002/(SICI)1098-2825(1999)13:1<35::AID-JCLA7>3.0.CO;2-R

Measurement of four tumor marker antigens in the sera of pregnant women

Carol D Cheli 1, Deborah L Morris 1, Irene E Neaman 1, Jian Dai 1, W Jeffrey Allard 1, Kwok K Yeung 1,✉
PMCID: PMC6807807  PMID: 10025736

Abstract

We sought to determine the maternal serum levels of four tumor‐associated antigens during the three trimesters of pregnancy in healthy women. CEA, CA 228, CA 15‐3, and Her2/neu oncogene product p105 assay values were determined for 90 healthy pregnant women during the three trimesters of pregnancy at five participating evaluation sites. Results were compared to means and cut‐off values determined for healthy nonpregnant women. Differences in assay values in the 1st and 3rd trimester were analyzed for statistical significance (Student's t‐test). CEA, CA 228 and CA 15‐3 assay values in general were found to be within the normal range. CA 15‐3 and Her2/neu p105 serum assay values were above the cut‐off (3.3% and 8.2%, respectively) and were significantly elevated in the 3rd trimester as compared to the 1st trimester of pregnancy (P < 0.05 and P < 0.001, respectively). CEA and CA 228 may be of potential value in monitoring pregnant women with malignant disease. Normal elevations in 3rd trimester serum Her2/neu p105 and CA 15‐3 assay values should be considered when monitoring a pregnant patient with malignant disease. J. Clin. Lab. Anal. 13:35–39, 1999. © 1999 Wiley‐Liss, Inc.

Keywords: tumor‐associated antigens, pregnancy, immunoassay, tumor markers, healthy women, Muc 1 mucin, NCA 50/90, carcinoembryonic antigen, c‐erbB‐2

REFERENCES

  • 1. Touitou Y, Bogdan A. Tumor markers in non‐malignant diseases. Eur J Clin Oncol 1988;24:1083–1091.Medline [DOI] [PubMed] [Google Scholar]
  • 2. Antonelli NM, Dotters DJ, Katz VL, Kuller JA. Cancer in pregnancy: A review of the literature. Part I. Obstet Gynecol Surv 1996;51:125–134. Medline [DOI] [PubMed] [Google Scholar]
  • 3. Stevenson J, Giantonio B, Boyd RL, Bruner JA. Adjuvant chemotherapy for breast cancer in pregnancy: Can recommendations be made with confidence? Semin Oncol 1997;24:xxvii–xxvix. [PubMed] [Google Scholar]
  • 4. Werner M, Faser C, Silverberg M. Clinical utility and validation of emerging biochemical markers for mammary adenocarcinoma. Clin Chem 1993;39:P11 Pt. 2:2386–2396. Medline [PubMed] [Google Scholar]
  • 5. Dnistrian AM, Schwarz MK, Greenburg, EJ , Smith CA, Schwarz DC. CA 15‐3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta 1991;200:81–94. Medline [DOI] [PubMed] [Google Scholar]
  • 6. Fletcher RH. Carcinoembyonic antigen. Ann Intern Med 1986;104:66–73. Medline [DOI] [PubMed] [Google Scholar]
  • 7. Fritsche HA. Serum tumor markers for patient monitoring: A case‐oriented approach illustrated with carcinoembryonic antigen. Clin Chem 1993;39:2431–2434. Medline [PubMed] [Google Scholar]
  • 8. Allard W, Neaman IE, Elting JJ, et al. Nonspecific cross‐reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer. Cancer Res 1994;54:1227–1234. Medline [PubMed] [Google Scholar]
  • 9. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c‐erbB‐2 gene: A 185 kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644–1646. Medline [DOI] [PubMed] [Google Scholar]
  • 10. Carney WP, Hamer PJ, Petit D, et al. Detection and quantitation of the human neu oncoprotein. J Tumor Mark Oncol 1991;6:53–72. [Google Scholar]
  • 12. Gu K, Mes‐Masson AM, Salad J, Saad F. Overexpression of her‐2/neu in human prostate cancer and benign hyperplasia. Cancer Lett 1996;99:185–189. Medline [DOI] [PubMed] [Google Scholar]
  • 13. Lelle RJ, Henkel E, Leinemann D, Goeschen K. Measurement of CEA, TPA, Neopterin, CA 125, CA 153 and CA 199 in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol Obstet Invest 1989;27:137–142. Medline [DOI] [PubMed] [Google Scholar]
  • 14. Correale M, Abbate I, Dragone CD, et al. Behavior of four serum tumor markers in pregnant women. Int J Biol Markers 1993;7:198–199. [DOI] [PubMed] [Google Scholar]
  • 15. Touitou Y, Darbios Y, Bogdan A, Auzeby A, Keusseoglou S. Tumour marker antigens during menses and pregnancy. Br J Cancer 1989;60:419–420. Medline [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA 15‐3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986;4:1542–1550. Medline [DOI] [PubMed] [Google Scholar]
  • 17. Schrocksndel H, Daxenbichler G, Artner E, Steckel‐Berger G, Dapunt O. Tumor markers in hypertensive disorders of pregnancy. Gynecol Obstet Invest 1993;35:204–208. [DOI] [PubMed] [Google Scholar]
  • 19. Meden H, Marx D, Fattahi A, et al. Elevated serum levels of a c‐erbB‐2 oncogene product in ovarian cancer patients and in pregnancy. J Cancer Res Clin Oncol 1994;120:378–381. Medline [DOI] [PubMed] [Google Scholar]
  • 20. Meden H, Miele S, Schauer A, Kuhn W. Serum levels of te c‐erbB‐2 (Her2/neu) encoded oncoprotein fragment p105 in normal pregnancies. In Vivo 1997;11:51–54. Medline [PubMed] [Google Scholar]
  • 21. Oehr P, Bellmann O, Hamann D. Measurement of Tennessee antigen, carcinoembryonic antigen, tissue polypeptide antigen and alpha‐feto‐protein in body fluids associated with pregnancy. Clin Biochem 1982;15(1):13–16. Medline [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES